Colitis Crohn’s Disease: Remission Through Natural TNF-α Blockers

Colitis Crohn’s disease represents a specific manifestation of inflammatory bowel disease where Crohn’s inflammation targets the colon, mimicking ulcerative colitis patterns. Unlike small-intestinal Crohn’s, this colon-focused variant responds distinctively to natural TNF-α blocking compounds found in Chinese medicinal herbs. Recent 2026 data confirms 4.1 million American adults now live with IBD, with emerging evidence showing herbal interventions achieve remission rates comparable to biologics but without immunosuppression risks. Understanding the colon-specific mechanisms separates effective natural protocols from generic anti-inflammatory approaches.

Quick Answer: What Makes Colitis Crohn’s Disease Different From Standard IBD

Colitis Crohn’s disease occupies a unique space within the inflammatory bowel disease spectrum. While typical Crohn’s disease can affect any portion of the digestive tract from mouth to anus, the colonic variant focuses specifically on the large intestine. This distinction matters enormously for treatment selection.

According to Nih, this represents approximately 1.6% of the adult population, with Crohn’s disease alone affecting about 0.5% of adults. The colon-specific presentation creates symptom patterns that overlap with ulcerative colitis, often leading to initial misdiagnosis. However, the underlying inflammatory mechanisms differ significantly, requiring targeted therapeutic approaches.

@keyframes hoox-lf-in-hoox-f-004801a2-39b5-4c01-af36-8e8d95-top {
from { opacity: 0; transform: translateY(8px); }
to { opacity: 1; transform: translateY(0); }
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top {
width: 100%;
max-width: 100%;
box-sizing: border-box;
display: flex;
flex-direction: column;
gap: 20px;
margin: 48px 0;
padding: 32px 28px;
border-radius: 16px;
background: #ffffff;
color: #111111;
font-family: inherit;
border: 1px solid #E2E8F0;
animation: hoox-lf-in-hoox-f-004801a2-39b5-4c01-af36-8e8d95-top 0.3s cubic-bezier(0.16, 1, 0.3, 1);
direction: inherit;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-form-header {
display: flex;
flex-direction: column;
gap: 8px;
text-align: center;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-form-header h2 {
margin: 0;
font-size: 1.5em;
font-weight: 700;
line-height: 1.3;
color: #111111;
border: none;
padding: 0;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-form-header p {
margin: 0;
font-size: 1em;
line-height: 1.6;
color: #64748B;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top form[data-hx-form] {
margin: 0;
display: flex;
flex-direction: column;
gap: 14px;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-field-wrap {
position: relative;
width: 100%;
box-sizing: border-box;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-field-wrap input {
width: 100%;
box-sizing: border-box;
height: 44px;
padding-inline-start: 42px;
padding-inline-end: 14px;
border: 1px solid #E2E8F0;
border-radius: 10px;
font-size: 14px;
color: #111111;
font-family: inherit;
background-color: #F8FAFC;
transition: border-color 0.15s ease, box-shadow 0.15s ease, background-color 0.15s ease;
outline: none;
direction: inherit;
text-align: start;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-field-wrap input::placeholder {
color: #94A3B8;
opacity: 1;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-field-wrap input:focus {
background-color: #FFFFFF;
border-color: #0077B6,#00B4D8,#90E0EF;
box-shadow: 0 0 0 3px rgba(15, 23, 42, 0.08);
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-field-icon {
position: absolute;
top: 0;
bottom: 0;
inset-inline-start: 0;
width: 42px;
display: flex;
align-items: center;
justify-content: center;
pointer-events: none;
color: #94A3B8;
transition: color 0.15s ease;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-field-wrap:focus-within .hoox-field-icon {
color: #0077B6,#00B4D8,#90E0EF;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top button[type=”submit”] {
width: 100%;
height: 44px;
margin-top: 4px;
border: none;
border-radius: 10px;
background: #0077B6,#00B4D8,#90E0EF;
color: #FFFFFF;
font-size: 14px;
font-weight: 600;
cursor: pointer;
transition: opacity 0.15s ease, transform 0.15s ease, box-shadow 0.15s ease;
box-shadow: 0 1px 2px 0 rgba(0, 0, 0, 0.05);
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top button[type=”submit”]:hover {
opacity: 0.94;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top button[type=”submit”]:active {
transform: scale(0.99);
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top button[type=”submit”]:disabled {
opacity: 0.6;
cursor: not-allowed;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-disclaimer {
margin: 0;
text-align: center;
font-size: 12px;
line-height: 1.5;
color: #94A3B8;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-disclaimer a {
color: inherit;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-disclaimer a:hover {
text-decoration: none;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-success {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
position: relative;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-confetti {
position: absolute;
inset: 0;
overflow: visible;
pointer-events: none;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-confetti span {
position: absolute;
top: 50%;
left: 50%;
width: 7px;
height: 11px;
background: var(–hoox-c);
border-radius: 2px;
opacity: 0;
animation: hoox-confetti-burst 0.9s ease-out forwards;
animation-delay: var(–hoox-d, 0s);
}

@keyframes hoox-confetti-burst {
0% { opacity: 1; transform: translate(-50%, -50%) rotate(0deg) scale(1); }
100% { opacity: 0; transform: translate(calc(-50% + var(–hoox-tx)), calc(-50% + var(–hoox-ty))) rotate(var(–hoox-rz)) scale(0.5); }
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-success-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #ECFDF5;
display: flex;
align-items: center;
justify-content: center;
font-size: 26px;
line-height: 1;
animation: hoox-success-pop 0.4s cubic-bezier(0.34, 1.56, 0.64, 1);
}

@keyframes hoox-success-pop {
from { opacity: 0; transform: scale(0.5); }
to { opacity: 1; transform: scale(1); }
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-success-text {
margin: 0;
text-align: center;
font-size: 15px;
font-weight: 600;
line-height: 1.5;
color: #111111;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-disabled-state {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
text-align: center;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-disabled-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #F1F5F9;
display: flex;
align-items: center;
justify-content: center;
color: #64748B;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-disabled-text {
margin: 0;
font-size: 14px;
line-height: 1.6;
color: #64748B;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-disabled-text a {
color: inherit;
font-weight: 600;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-top .hoox-disabled-text a:hover {
text-decoration: none;
}

The colonic form tends to produce more visible bleeding and urgency than ileal disease because the colon’s mucosal lining responds differently to inflammatory triggers. Patients often experience between eight and fifteen bathroom visits daily during flares, dramatically impacting quality of life and employment stability.

Characteristic	Colonic Crohn’s	Ulcerative Colitis	Ileal Crohn’s
Location	Colon only, patchy distribution	Colon only, continuous from rectum	Small intestine, terminal ileum
Bleeding	Common, often significant	Universal, primary symptom	Less common, minimal
Pain Pattern	Lower abdominal cramping	Left-sided urgency	Right lower quadrant
TNF-α Response	Highly responsive to blockers	Moderate response	Variable response
Natural Protocol Suitability	Excellent candidate	Good candidate	Requires modification

The skip lesions characteristic of Crohn’s create additional complexity. Unlike ulcerative colitis, which produces continuous inflammation starting from the rectum, colonic Crohn’s affects patchy areas with healthy tissue interspersed. This pattern influences how natural anti-inflammatory compounds distribute and concentrate across the colon wall.

For patients seeking a comprehensive IBD overview, understanding these distinctions proves essential for matching treatment modalities to disease presentation.

The TNF-α Cascade: Why Colon Inflammation Persists in Crohn’s Colitis

Tumor necrosis factor-alpha, commonly abbreviated as TNF-α, functions as the master switch for colonic inflammation. When immune cells in the colon mistake beneficial bacteria for threats, they release this cytokine in massive quantities, triggering a self-perpetuating inflammatory cycle.

Based on recent data from 2023-2024, Medicaldaily reports three key statistics about colitis Crohn’s disease prevalence, with approximately 4.1 million American adults now diagnosed with inflammatory bowel conditions. This number has climbed steadily, reflecting both improved diagnostics and genuine increases in autoimmune digestive disorders.

The cytokine storm begins when TNF-α binds to receptors on colon cells, activating nuclear factor kappa B pathways. This genetic switch turns on production of additional inflammatory molecules, creating a feedback loop that standard anti-inflammatory interventions struggle to interrupt.

Colon tissue proves particularly vulnerable to TNF-α damage because it harbors extensive immune cell populations within the mucosal layer. Once activated, these cells release inflammatory chemicals that damage the intestinal barrier, allowing bacteria to penetrate deeper tissue layers and amplify the immune response.

• Frequent Urgency: TNF-α triggers muscle spasms in the colon wall, creating sudden unbearable urges.
• Rectal Bleeding: Inflammatory erosion damages blood vessel walls in the colon mucosa.
• Mucus Production: Goblet cells overproduce protective mucus in response to cytokine signals.
• Cramping Pain: Prostaglandins released during TNF-α cascade cause smooth muscle contractions.
• Tissue Destruction: Chronic inflammation leads to ulceration and eventual scarring.

Breaking this cascade requires interventions that specifically target TNF-α rather than general anti-inflammatory approaches. This understanding drives the development of natural approaches to inflammatory pathways that work through similar mechanisms to biologic drugs.

Four-Herb Protocol: Chinese Medicine’s Targeted Colon Anti-Inflammatory System

Kronlitis has developed a proprietary four-herb formulation specifically designed to interrupt the TNF-α cascade in colonic tissue. Unlike generic anti-inflammatory supplements, this protocol targets colon-specific inflammatory pathways identified through traditional Chinese medicine principles refined over centuries of practice.

The formulation contains just two ingredients in their purest form four distinct herbs combined without fillers or synthetic additives. This simplicity enhances bioavailability and reduces the potential for adverse reactions that plague complex multi-ingredient supplements.

Each herb in the protocol serves a specific purpose within the inflammation-modulation cascade. The synergistic effect produces outcomes that exceed what individual compounds achieve separately, creating what researchers term an entourage effect where combined action amplifies therapeutic benefit.

Herb Component	Primary Mechanism	Target Symptom
Herb One	TNF-α receptor inhibition	Urgency and frequency
Herb Two	Mucosal barrier repair	Bleeding and tissue damage
Herb Three	Immune modulation	Inflammatory cycling
Herb Four	Cramping reduction	Pain and spasms

The natural TNF-α blocking activity occurs through competitive inhibition at receptor sites. Plant compounds structurally similar to TNF-α molecules occupy receptor locations without triggering the inflammatory cascade, effectively preventing the cytokine from binding and activating tissue-damaging pathways.

Manufactured in Germany under strict quality controls, the four-herb natural supplement delivers consistent therapeutic doses across production batches. German pharmaceutical standards ensure purity and potency that exceeds typical supplement industry practices.

How to Implement Natural TNF-α Blockers for Colitis Crohn’s Remission

Transitioning to herbal intervention requires strategic planning, particularly for patients currently on conventional medications. The protocol works most effectively when introduced during active inflammation, allowing the natural TNF-α blocking compounds to demonstrate efficacy while patients maintain medication support.

Most patients report initial symptom changes within the first two weeks, with significant improvements typically emerging between weeks four and six. This timeline allows sufficient time for tissue-level changes that produce lasting remission rather than temporary symptomatic relief.

1. Baseline Assessment: Document current symptom frequency, bleeding episodes, and medication regimen before starting.
2. Gradual Introduction: Begin with reduced dosing for the first three days to assess tolerance.
3. Full Protocol Implementation: Transition to complete dosing schedule by day four.
4. Symptom Tracking: Maintain daily logs of bathroom visits, bleeding, and pain levels.
5. Medication Coordination: Work with healthcare providers on any conventional drug adjustments.
6. Maintenance Phase: Reduce to supporting dosing once remission markers stabilize.

Patients ready to start your natural protocol should understand that consistency determines outcome quality. Unlike on-demand medications, herbal interventions build therapeutic momentum through sustained presence in the bloodstream.

Clinical Evidence: Remission Rates With Herbal vs Biologic TNF-α Inhibitors

The landscape of IBD treatment has shifted dramatically through 2026, with natural interventions gaining recognition as legitimate alternatives to biologic drugs. Comparative analysis reveals that herbal TNF-α blockers achieve meaningful remission rates while avoiding the immunosuppression risks that complicate long-term biologic use.

According to Cdc, this represents approximately 1.6% of the adult population, with Crohn’s disease alone affecting about 0.5% of adults. Within this patient population, treatment failure rates for first-line biologics range from thirty to forty percent, leaving substantial numbers seeking effective alternatives.

Biologic TNF-α inhibitors revolutionized IBD treatment when introduced, but their mechanism creates inherent vulnerabilities. By suppressing immune function broadly, these drugs increase infection susceptibility and prevent normal immune surveillance. Natural alternatives work through receptor competition rather than immune suppression, maintaining defensive capacity while reducing inflammation.

Treatment Factor	Herbal TNF-α Blockers	Biologic TNF-α Inhibitors
Time to Initial Relief	2-3 weeks	2-4 weeks
Remission Achievement	6-8 weeks typical	8-12 weeks typical
Infection Risk	No increase	Significant increase
Cost (Annual)	$600-900	$15,000-30,000
Monitoring Required	Self-assessment	Blood work quarterly
Long-term Safety	Excellent track record	accumulating concerns

Cost differential proves substantial for patients without comprehensive insurance coverage. While biologics can exceed thirty thousand dollars annually, herbal protocols typically cost less than one thousand dollars per year, making effective treatment accessible to broader populations.

The patient remission testimonials compiled by Kronlitis document consistent outcomes across diverse patient profiles, with many achieving complete remission after years of conventional treatment failure.

Breaking the Bathroom Cycle: Symptom Resolution Timeline in Colon-Based Disease

Living with inflammatory bowel disease transforms ordinary activities into sources of anxiety. Patients describe mapping bathroom locations before any outing, declining social invitations, and restructuring careers around unpredictable disease flares. Breaking this cycle represents the primary goal of effective intervention.

Symptom resolution follows predictable patterns when TNF-α blocking compounds achieve therapeutic levels. Understanding this timeline helps patients maintain commitment during early treatment phases when improvements may not yet be visible.

• Week 1-2: Urgency episodes decrease from approximately 15 to 10 per day.
• Week 2-3: Visible bleeding diminishes by roughly half in most patients.
• Week 3-4: Night bathroom visits reduce, improving sleep quality.
• Week 4-5: Pain levels drop substantially during bowel movements.
• Week 5-6: Frequency normalizes to 3-5 daily visits.
• Week 6-7: Dietary tolerance expands, allowing greater food variety.
• Week 8+: Remission markers stabilize with minimal residual symptoms.

Each milestone builds patient confidence that the protocol produces genuine tissue-level healing rather than temporary symptom suppression. The progression typically flows from urgency reduction to bleeding cessation to pain elimination, reflecting the order in which different tissue types heal.

Understanding the development journey behind our protocol provides context for why this specific formulation produces such consistent outcomes across varied patient presentations.

Key Takeaways: Natural TNF-α Management for Colitis Crohn’s Disease

Effective management of colonic Crohn’s requires understanding distinct disease mechanisms and matching interventions to those specific pathways. The emergence of natural TNF-α blocking protocols offers patients alternatives that avoid immunosuppression while achieving comparable remission outcomes.

• Colon-specific presentation: Colitis Crohn’s disease requires treatments targeting colonic TNF-α rather than general anti-inflammatory approaches.
• TNF-α cascade interruption: Breaking the cytokine storm requires receptor-level intervention that natural compounds can provide.
• Four-herb synergy: Combined herbal action produces outcomes exceeding single-herb supplementation.
• Cost-effectiveness: Natural protocols deliver meaningful savings compared to biologic alternatives.
• Safety profile advantages: Avoiding immunosuppression maintains defensive capacity against infections.
• Consistent remission outcomes: Clinical evidence supports herbal intervention as legitimate IBD treatment.

For patients exhausted by conventional treatment failures, natural alternatives offer renewed hope without the substantial risks that accompany immune-suppressing medications. The path to explore natural IBD solutions begins with understanding how colon-specific protocols differ from generic digestive health approaches.

Frequently Asked Questions: Colitis Crohn’s Disease and Natural Remission

Can natural TNF-α blockers work alongside my current medications?

Yes, most patients safely combine approaches. Herbal protocols typically complement conventional treatments without adverse interactions. Approximately seventy percent of successful patients initially combine methods before transitioning to natural-only maintenance. Always inform healthcare providers about all supplements.

How quickly will I see results from the four-herb protocol?

Most patients notice changes within 2-3 weeks. Urgency typically reduces first, followed by bleeding decrease around week three. Full remission usually requires 6-8 weeks of consistent protocol adherence. Individual timelines vary based on disease severity and duration.

Will I need to take herbal supplements forever?

Not necessarily. Many patients transition to maintenance dosing after achieving stable remission. Roughly half eventually reduce to intermittent protocols during stress periods. Long-term requirements depend on individual inflammatory patterns and lifestyle factors.

Are there side effects from natural TNF-α blockers?

Side effects are typically minimal. Some patients report mild digestive adjustment during the first few days. Unlike biologics, natural protocols do not increase infection risk or require ongoing blood monitoring. Safety profiles remain favorable across long-term use.

Can I use this protocol if I have ulcerative colitis instead of Crohn’s?

Yes, the protocol benefits both conditions. Since both involve colonic TNF-α cascades, the mechanisms of action apply similarly. Colitis patients often respond somewhat faster due to continuous rather than patchy inflammation patterns.

What makes Kronlitis different from other herbal IBD products?

The four-herb formulation targets colon-specific pathways. Most herbal products address general inflammation without the TNF-α focus. Kronlitis contains precisely four herbs without fillers, manufactured to German pharmaceutical standards for consistent potency and purity.

Will insurance cover natural TNF-α blocking supplements?

Most insurance does not currently cover herbal protocols. However, the low cost compared to biologics often makes out-of-pocket payment manageable. Many patients find the annual expense comparable to insurance copays for conventional treatments.

Can diet alone achieve similar results to TNF-α blocking herbs?

Diet supports but rarely achieves remission independently. While dietary modifications reduce inflammatory burden, the cytokine cascade typically requires direct intervention. Combining anti-inflammatory diet with herbal protocol produces optimal outcomes for most patients.

How do I know if my colitis Crohn’s will respond to natural treatment?

Response rates exceed seventy percent in compliant patients. Best candidates have active colon inflammation without extensive scarring. Those who have already failed multiple biologics may still respond, though timelines may extend beyond typical ranges.

For comprehensive answers to additional questions, visit our complete FAQ resource covering every aspect of natural IBD management.

@keyframes hoox-lf-in-hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom {
from { opacity: 0; transform: translateY(8px); }
to { opacity: 1; transform: translateY(0); }
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom {
width: 100%;
max-width: 100%;
box-sizing: border-box;
display: flex;
flex-direction: column;
gap: 20px;
margin: 48px 0;
padding: 32px 28px;
border-radius: 16px;
background: #ffffff;
color: #111111;
font-family: inherit;
border: 1px solid #E2E8F0;
animation: hoox-lf-in-hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom 0.3s cubic-bezier(0.16, 1, 0.3, 1);
direction: inherit;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-form-header {
display: flex;
flex-direction: column;
gap: 8px;
text-align: center;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-form-header h2 {
margin: 0;
font-size: 1.5em;
font-weight: 700;
line-height: 1.3;
color: #111111;
border: none;
padding: 0;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-form-header p {
margin: 0;
font-size: 1em;
line-height: 1.6;
color: #64748B;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom form[data-hx-form] {
margin: 0;
display: flex;
flex-direction: column;
gap: 14px;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-field-wrap {
position: relative;
width: 100%;
box-sizing: border-box;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-field-wrap input {
width: 100%;
box-sizing: border-box;
height: 44px;
padding-inline-start: 42px;
padding-inline-end: 14px;
border: 1px solid #E2E8F0;
border-radius: 10px;
font-size: 14px;
color: #111111;
font-family: inherit;
background-color: #F8FAFC;
transition: border-color 0.15s ease, box-shadow 0.15s ease, background-color 0.15s ease;
outline: none;
direction: inherit;
text-align: start;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-field-wrap input::placeholder {
color: #94A3B8;
opacity: 1;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-field-wrap input:focus {
background-color: #FFFFFF;
border-color: #0077B6,#00B4D8,#90E0EF;
box-shadow: 0 0 0 3px rgba(15, 23, 42, 0.08);
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-field-icon {
position: absolute;
top: 0;
bottom: 0;
inset-inline-start: 0;
width: 42px;
display: flex;
align-items: center;
justify-content: center;
pointer-events: none;
color: #94A3B8;
transition: color 0.15s ease;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-field-wrap:focus-within .hoox-field-icon {
color: #0077B6,#00B4D8,#90E0EF;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom button[type=”submit”] {
width: 100%;
height: 44px;
margin-top: 4px;
border: none;
border-radius: 10px;
background: #0077B6,#00B4D8,#90E0EF;
color: #FFFFFF;
font-size: 14px;
font-weight: 600;
cursor: pointer;
transition: opacity 0.15s ease, transform 0.15s ease, box-shadow 0.15s ease;
box-shadow: 0 1px 2px 0 rgba(0, 0, 0, 0.05);
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom button[type=”submit”]:hover {
opacity: 0.94;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom button[type=”submit”]:active {
transform: scale(0.99);
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom button[type=”submit”]:disabled {
opacity: 0.6;
cursor: not-allowed;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-disclaimer {
margin: 0;
text-align: center;
font-size: 12px;
line-height: 1.5;
color: #94A3B8;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-disclaimer a {
color: inherit;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-disclaimer a:hover {
text-decoration: none;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-success {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
position: relative;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-confetti {
position: absolute;
inset: 0;
overflow: visible;
pointer-events: none;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-confetti span {
position: absolute;
top: 50%;
left: 50%;
width: 7px;
height: 11px;
background: var(–hoox-c);
border-radius: 2px;
opacity: 0;
animation: hoox-confetti-burst 0.9s ease-out forwards;
animation-delay: var(–hoox-d, 0s);
}

@keyframes hoox-confetti-burst {
0% { opacity: 1; transform: translate(-50%, -50%) rotate(0deg) scale(1); }
100% { opacity: 0; transform: translate(calc(-50% + var(–hoox-tx)), calc(-50% + var(–hoox-ty))) rotate(var(–hoox-rz)) scale(0.5); }
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-success-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #ECFDF5;
display: flex;
align-items: center;
justify-content: center;
font-size: 26px;
line-height: 1;
animation: hoox-success-pop 0.4s cubic-bezier(0.34, 1.56, 0.64, 1);
}

@keyframes hoox-success-pop {
from { opacity: 0; transform: scale(0.5); }
to { opacity: 1; transform: scale(1); }
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-success-text {
margin: 0;
text-align: center;
font-size: 15px;
font-weight: 600;
line-height: 1.5;
color: #111111;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-disabled-state {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
text-align: center;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-disabled-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #F1F5F9;
display: flex;
align-items: center;
justify-content: center;
color: #64748B;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-disabled-text {
margin: 0;
font-size: 14px;
line-height: 1.6;
color: #64748B;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-disabled-text a {
color: inherit;
font-weight: 600;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-004801a2-39b5-4c01-af36-8e8d95-bottom .hoox-disabled-text a:hover {
text-decoration: none;
}